Neutrophil gelatinase-associated lipocalin (NGAL) in chronic cardiorenal failure is correlated with endogenous erythropoietin levels and decreases in response to low-dose erythropoietin treatment

Kidney and Blood Pressure Research

Volumn 36, Issue 1, 2012, Pages 344-354

  Emans, Mireille E ^a   Braam, Branko ^b   Diepenbroek, Adry ^c   Van Der Putten, Karien ^d   Cramer, Maarten J ^a   Wielders, Jos P M ^c   Swinkels, Dorine W ^e   Doevendans, Pieter A ^a,f   Gaillard, Carlo A ^c,g  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF ALBERTA   (Canada)

^c MEANDER MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biomarkers; Cardiorenal syndrome; Chronic heart failure; Chronic kidney disease; Erythropoietin; Iron homeostasis; NGAL

Indexed keywords

CREATININE; CYSTATIN C; ERYTHROPOIETIN; HEMOGLOBIN; HEPCIDIN; HEPCIDIN 25; IRON; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; CARDIORENAL SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; FEMALE; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON METABOLISM; IRON STORAGE; KIDNEY TUBULE DAMAGE; LOW DRUG DOSE; MALE; MICROALBUMINURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE HEMOGLOBIN CONTENT; TREATMENT DURATION; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL;

ACUTE-PHASE PROTEINS; AGED; AGED, 80 AND OVER; ANEMIA; ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL MARKERS; CHRONIC DISEASE; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; FEMALE; HEART FAILURE; HUMANS; IRON; LIPOCALINS; MALE; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; REGRESSION ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; TRANSFERRIN;

EID: 84870727105     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000343392     Document Type: Article

References (33)

1. Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J, Schmidt-Ott KM, Chen X, Li JY, Weiss S, Mishra J, Cheema FH, Markowitz G, Suganami T, Sawai K, Mukoyama M, Kunis C, D'Agati V, Devarajan P, Barasch J: Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005;115:610-621.
2. Schilcher G, Ribitsch W, Otto R, Portugaller RH, Quehenberger F, Truschnig-Wilders M, Zweiker R, Stiegler P, Brodmann M, Weinhandl K, Horina JH: Early detection and intervention using neutrophil gelatinase-associated lipocalin (ngal) may improve renal outcome of acute contrast media induced nephropathy: A randomized controlled trial in patients undergoing intra-arterial angiography (anti-cin study). BMC Nephrol 2011;12:39.
3. Bolignano D, Donato V, Coppolino G, Campo S, Buemi A, Lacquaniti A, Buemi M: Neutrophil gelatinase-associated lipocalin (ngal) as a marker of kidney damage. Am J Kidney Dis 2008;52:595-605.
4. Dent CL, Ma Q, Dastrala S, Bennett M, Mitsnefes MM, Barasch J, Devarajan P: Plasma neutrophil gelatinase-associated lipocalin predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: A prospective uncontrolled cohort study. Crit Care 2007;11:R127.
5. Bolignano D, Lacquaniti A, Coppolino G, Campo S, Arena A, Buemi M: Neutrophil gelatinase-associated lipocalin reflects the severity of renal impairment in subjects affected by chronic kidney disease. Kidney Blood Press Res 2008;31:255-258.
6. Poniatowski B, Malyszko J, Bachorzewska-Gajewska H, Malyszko JS, Dobrzycki S: Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in patients with chronic heart failure and coronary artery disease. Kidney Blood Press Res 2009;32:77-80.
7. Jungbauer CG, Birner C, Jung B, Buchner S, Lubnow M, von Bary C, Endemann D, Banas B, Mack M, Boger CA, Riegger G, Luchner A: Kidney injury molecule-1 and n-acetyl-ss-d-glucosaminidase in chronic heart failure: Possible biomarkers of cardiorenal syndrome. Eur J Heart Failure 2011;13:1104-1110.
8. Damman K, Masson S, Hillege HL, Maggioni AP, Voors AA, Opasich C, van Veldhuisen DJ, Montagna L, Cosmi F, Tognoni G, Tavazzi L, Latini R: Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J 2011;32:2705-2712.
9. Maisel AS, Mueller C, Fitzgerald R, Brikhan R, Hiestand BC, Iqbal N, Clopton P, van Veldhuisen DJ: Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: The ngal evaluation along with b-type natriuretic peptide in acutely decompensated heart failure (gallant) trial. Eur J Heart Failure 2011;13:846-851.
10. Yang J, Goetz D, Li JY, Wang W, Mori K, Setlik D, Du T, Erdjument-Bromage H, Tempst P, Strong R, Barasch J: An iron delivery pathway mediated by a lipocalin. Mol Cell 2002;10:1045-1056.
11. Malyszko J, Malyszko JS, Kozminski P, Koc-Zorawska E, Mysliwiec M, Macdougall I: Possible relationship between neutrophil gelatinase-associated lipocalin, hepcidin, and inflammation in haemodialysed patients. Nephron Clin Practice 2010;115:c268-c275.
12. Bolignano D, Coppolino G, Romeo A, De Paola L, Buemi A, Lacquaniti A, Nicocia G, Lombardi L, Buemi M: Neutrophil gelatinase-associated lipocalin (ngal) reflects iron status in haemodialysis patients. Nephrol Dial Transplant 2009;24:3398-3403.
13. Malyszko J, Tesar V, Macdougall IC: Neutrophil gelatinase-associated lipocalin and hepcidin: What do they have in common and is there a potential interaction? Kidney Blood Press Res 2010;33:157-165.
14. Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA: Disordered iron homeostasis in chronic heart failure: Prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol 2011;58:1241-1251.
15. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJV, Anker SD, Ponikowski P: Iron deficiency: An ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010;31:1872-1880.
16. van der Putten K, Jie KE, van den Broek D, Kraaijenhagen RJ, Laarakkers C, Swinkels DW, Braam B, Gaillard CA: Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients. Eur J Heart Fail 2010;12:943-950.
17. Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW: Hepcidin in human iron disorders: Diagnostic implications. Clin Chem 2011;57:1650-1669.
18. van der Putten K, Jie KE, Emans ME, Verhaar MC, Joles JA, Cramer MJ, Velthuis BK, Meiss L, Kraaijenhagen RJ, Doevendans PA, Braam B, Gaillard CA: Erythropoietin treatment in patients with combined heart and renal failure: Objectives and design of the epocares study. J Nephrol 2010;23:363-368.
19. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Tendera M, Auricchio A, Bax J, Bohm M, Corra U, della Bella P, Elliott PM, Follath F, Gheorghiade M, Hasin Y, Hernborg A, Jaarsma T, Komajda M, Kornowski R, Piepoli M, Prendergast B, Tavazzi L, Vachiery JL, Verheugt FW, Zamorano JL, Zannad F: Esc guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the european society of cardiology. Developed in collaboration with the heart failure association of the esc (hfa) and endorsed by the european society of intensive care medicine (esicm). Eur J Heart Fail 2008;10:933-989.
20. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbely A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL: How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the heart failure and echocardiography associations of the european society of cardiology. Eur Heart J 2007;28:2539-2550.
21. Kroot JJC, Laarakkers CMM, Geurts-Moespot AJ, Grebenchtchikov N, Pickkers P, van Ede AE, Peters HPE, van Dongen-Lases E, Wetzels JFM, Sweep FCGJ, Tjalsma H, Swinkels DW: Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders. Clin Chem 2010;56:1570-1579.
22. Swinkels DW, Girelli D, Laarakkers C, Kroot J, Campostrini N, Kemna EH, Tjalsma H: Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PLoS One 2008;3:e2706.
23. Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, Klaver SM, Kroot JJ, van Tienoven D, Wetzels JF, Kiemeney LA, Sweep FC, den Heijer M, Swinkels DW: Serum hepcidin: Reference ranges and biochemical correlates in the general population. Blood 2011;117:e218-225.
24. Duh MS, Lefebvre P, Fastenau J, Piech CT, Waltzman RJ: Assessing the clinical benefits of erythropoietic agents using area under the hemoglobin change curve. Oncologist 2005;10:438-448.
25. Singer E, Elger A, Elitok S, Kettritz R, Nickolas TL, Barasch J, Luft FC, Schmidt-Ott KM: Urinary neutrophil gelatinase-associated lipocalin distinguishes pre-renal from intrinsic renal failure and predicts outcomes. Kidney Int 2011;80:405-414.
26. Han M, Li Y, Liu M, Cong B: Renal neutrophil gelatinase associated lipocalin expression in lipopolysaccharide-induced acute kidney injury in the rat. BMC Nephrol 2012;13:25.
27. Machiguchi T, Yoshida H, Yonemoto S, Minakata T, Nomura K, Muso E, Tamura T, Sasayama S: Does circulating erythropoietin reflect progression of iga nephropathy? Comparison with urinary n-acetyl-beta-d-glucosaminidase. Nephrol Dial Transplant 1999;14:635-640.
28. Bahlmann FH, Song R, Boehm SM, Mengel M, von Wasielewski R, Lindschau C, Kirsch T, de Groot K, Laudeley R, Niemczyk E, Guler F, Menne J, Haller H, Fliser D: Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial akt and attenuates progressive organ failure. Circulation 2004;110:1006-1012.
29. Menne J, Park JK, Shushakova N, Mengel M, Meier M, Fliser D: The continuous erythropoietin receptor activator affects different pathways of diabetic renal injury. J Am Soc Nephrol 2007;18:2046-2053.
30. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC: Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial. Kidney Int 2004;66:753-760.
31. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098.
32. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-2084.
33. Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, Barasch J: Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2007;18:407-413.